For example, the results of CheckMate-227 study suggested, treated with nivolumab in combination with ipilimumab, a response rate (ORR) of 35.9% was achieved in NSCLC patients with PD-L1 TPS ≥1% (20). This evidence concerns the gene CD274 and non-small cell lung carcinoma.